What is XARELTO®?
XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions and no requirements for frequent blood tests.
Treats DVT and PE
In two clinical studies, almost 98% of adults being treated for a DVT or PE with XARELTO® did not have another one.§
§2.1% of patients treated with XARELTO® experienced another DVT vs 3.0% of patients treated with enoxaparin/vitamin K antagonist (EINSTEIN DVT). 2.1% of patients treated with XARELTO® experienced another PE vs 1.8% of patients treated with enoxaparin/vitamin K antagonist (EINSTEIN PE). Patients were followed for an average length of 208 days. People taking XARELTO® to treat a DVT or PE showed a major bleeding rate of 1% with XARELTO® vs 1.7% with enoxaparin and vitamin K antagonist.
Reduces the risk of another DVT and PE from happening again
In another clinical study, almost 99% of adults taking XARELTO® did not have another DVT or PE after 6 months of initial treatment for blood clots.||
||XARELTO® was superior to aspirin in reducing the risk of DVT/PE. After receiving treatment for blood clots for at least 6 months, 1.2% of patients on XARELTO® experienced another DVT or PE vs 4.4% on aspirin at 1 year (EINSTEIN CHOICE). Less than 1% of patients taking XARELTO® experienced major bleeding, which is similar to the rate of major bleeding in patients taking aspirin to reduce their risk of recurrent DVT or PE.

How do you take XARELTO®?
For DVT or PE, take XARELTO® 1 or 2 times a day as prescribed by your doctor
Are there any side effects associated with XARELTO® in adults?
Side effects of XARELTO®:
Your risk of bleeding increases if you take XARELTO® with other medicines that also increase your risk of bleeding, such as:

Getting started with XARELTO®?
Discover information about getting started with XARELTO®, savings options, and your condition—all in one helpful starter kit.